Moreover, combining immunotherapy with ionizing radiation or DNA-damaging chemotherapy may enhance PD-L1 expression, thereby expanding the therapeutic applicability of immune checkpoint inhibitors in high-grade neuroendocrine tumors (20). The gene discussed is CD274; the disease is neuroendocrine neoplasm.